Exam (elaborations)

TEST BANK Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition Teri Moser Woo and Wendy L. Wright Updated Version

0 purchase

Course
Pharmacotherapeutics for Advanced Practice

Institution
Pharmacotherapeutics For Advanced Practice

TEST BANK Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition Teri Moser Woo and Wendy L. Wright Updated Version 6th Edition Teri Moser Woo and Wendy L. Wright 6th Edition Teri Moser Woo and Wendy L. Wright 6th Edition Teri Moser Woo and Wendy L. Wright

[Show more]

Preview 4 out of 108 pages

View example

Uploaded on February 2, 2025
Number of pages 108
Written in 2024/2025
Type Exam (elaborations)
Contains Questions & answers

6th edition
test bank pharmacotherapeutics for advanced
pharmacotherapeutics for advanced practice
advanced practice nurse prescribers
6th edition teri moser woo and wendy l wright

Institution Pharmacotherapeutics for Advanced Practice
Course Pharmacotherapeutics for Advanced Practice

DrREED Member since 2 year 48 documents sold

687

$25.49

Add to cart

Save

100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached

TEST BANK
TABLE OF CONTENT

Chapter 1. The Role of the Advanced Practice Nurse as Prescriber ..................................................................... 4
Chapter 2. Review of Basic Principles of Pharmacology ..................................................................................... 5
Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition Chapter 3. Rational Drug Selection .................................................................................................................... 11
Author: Teri Moser Woo and Wendy L. Wright Chapter 4. Legal and Professional Issues in Prescribing .................................................................................... 14
Chapter 5. Adverse Drug Reactions.................................................................................................................... 16
Chapter 6. An Introduction to Pharmacogenomics ............................................................................................. 19
Chapter 7. Nutrition and Nutraceuticals ............................................................................................................. 22
Chapter 8. Herbal Therapies ............................................................................................................................... 28
Chapter 9. Cannabis ............................................................................................................................................ 31
Chapter 10. Pharmacoeconomics ........................................................................................................................ 35
Chapter 11. Drugs Affecting the Autonomic Nervous System........................................................................... 38
Chapter 12. Drugs Affecting the Central Nervous System ................................................................................. 45
Chapter 13. Drugs Affecting the Cardiovascular and Renal Systems ................................................................ 53
Chapter 14. Drugs Affecting the Respiratory System ........................................................................................ 61
Chapter 15. Drugs Affecting the Hematological System.................................................................................... 65
Chapter 16. Drugs Affecting the Immune System: Vaccines and Immunoglobulins ......................................... 69
Chapter 17. Drugs Affecting the Immune System: Immunomodulators ............................................................ 75
Chapter 18. Drugs Affecting the Gastrointestinal System .................................................................................. 77
Chapter 19. Drugs Affecting the Endocrine System: Pancreatic Hormones and Antidiabetic Drugs ................. 80
Chapter 20. Drugs Affecting the Endocrine System: Pituitary, Thyroid, and Adrenal Drugs ........................... 83
Chapter 21. Drugs Affecting the Reproductive System...................................................................................... 86
Chapter 22. Drugs Affecting the Bones and Joints ............................................................................................. 92
Chapter 23. Drugs Affecting the Integumentary System .................................................................................... 96
Chapter 24. Drugs Used to Treat Bacterial Infections ...................................................................................... 101
Chapter 25. Drugs Used to Treat Viral, Fungal, and Protozoal Infections ....................................................... 105
Chapter 26. Drugs Used to Treat Inflammatory Processes ............................................................................... 108
Chapter 27. Drugs Used to Treat Eye and Ear Disorders ................................................................................. 111
Chapter 28. Anemia .......................................................................................................................................... 113
Chapter 29. Anxiety and Depression ................................................................................................................ 116
Chapter 30. Attention Deficit-Hyperactivity Disorder ..................................................................................... 120
Chapter 31. Asthma and Allergy ...................................................................................................................... 122
Chapter 32. Chronic Obstructive Pulmonary Disease ...................................................................................... 125
Chapter 33. Contraception ................................................................................................................................ 127
Chapter 34. COVID-19: Acute and Chronic..................................................................................................... 130
Chapter 35. Dermatological Conditions ........................................................................................................... 134
Chapter 36. Diabetes Management ................................................................................................................... 138
Chapter 37. Gastroesophageal Reflux and Peptic Ulcer Disease ..................................................................... 146
Chapter 38. Headaches...................................................................................................................................... 149
Chapter 39. Heart Failure .................................................................................................................................. 153
Chapter 40. HIV Disease and Acquired Immunodeficiency Syndrome ........................................................... 158
Chapter 41. Menopausal Hormone Therapy ..................................................................................................... 161

,Chapter 42. Hyperlipidemia .............................................................................................................................. 164
Woo 1
Chapter 43. Hypertension ................................................................................................................................. 169 Pharmacotherapeutics for APN Prescribers, 6e Ch01
Chapter 44. Hyperthyroidism and Hypothyroidism.......................................................................................... 174
Chapter 45. Obesity .......................................................................................................................................... 177 Chapter 1. The Role of the Advanced Practice Nurse as Prescriber
Chapter 46. Pain Management: Acute and Chronic Pain ................................................................................. 181
Chapter 47. Pneumonia ..................................................................................................................................... 185
MULTIPLE CHOICE
Chapter 48. Sexually Transmitted Diseases and Vaginitis ............................................................................... 187
Chapter 49. Substance Use Disorders ............................................................................................................... 190 1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
Chapter 50. Tuberculosis .................................................................................................................................. 195
B. The U.S. Drug Enforcement Administration
Chapter 51. Upper Respiratory Tract Infection, Pharyngitis, Sinusitis, Otitis Media, and Otitis Externa ........ 197 C. The State Board of Nursing for each state
Chapter 52. Urinary Tract Infections ................................................................................................................ 200 D. The State Board of Pharmacy
Chapter 53. Women as Patients ........................................................................................................................ 203 ANS: C PTS: 1
Chapter 54. Men as Patients.............................................................................................................................. 207
2. The benefits to the patient of having an advanced practice registered nurse (APRN) prescriber
Chapter 55. Pediatric Patients ........................................................................................................................... 209 include:
Chapter 57. Geriatric Patients ........................................................................................................................... 213 A. Nurses know more about pharmacology than other prescribers because they take it
both in their basic nursing program and in their APRN program.
B. Nurses care for the patient from a holistic approach and include the patient in
decision-making regarding their care.
C. APRNs are less likely to prescribe narcotics and other controlled substances.
D. APRNs are able to prescribe independently in all states, whereas a physician’s
assistant needs to have a physician supervising their practice.
ANS: B PTS: 1

3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
ANS: A PTS: 1

4. The process for choosing an effective drug for a disorder includes:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration guidelines for prescribing
ANS: B PTS: 1

5. Nonintentional nonadherence of drug therapy may occur due to:
A. Belief that medication does not work
B. Adverse drug reactions
C. Chronic conditions that require daily therapy
D. Forgetfulness or distraction
ANS: D PTS: 1

, Woo 1 Woo 2
Pharmacotherapeutics for APN Prescribers, 6e Ch02 Pharmacotherapeutics for APN Prescribers, 6e Ch02

Chapter 2. Review of Basic Principles of Pharmacology A. Nonreceptor mechanism
B. Partial agonist
C. Full agonist
MULTIPLE CHOICE D. Noncompetitive antagonist

1. A patient’s nutritional intake and laboratory results reflect hypoalbuminemia. This is critical ANS: A PTS: 1
to prescribing because:
A. Distribution of drugs to target tissue may be affected. 7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic
B. The solubility of the drug will not match the site of absorption. effect is the:
A. Minimum adverse effect level
C. There will be less free drug available to generate an effect.
B. Peak of action
D. Drugs bound to albumin are readily excreted by the kidneys.
C. Onset of action
ANS: A PTS: 1 D. Therapeutic range

2. Drugs that have a significant first-pass effect: ANS: C PTS: 1
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation 8. Phenytoin requires that a trough level be drawn. Peak and trough levels are done:
A. When the drug has a wide therapeutic range
C. Are rapidly metabolized by the liver and may have little, if any, desired action
B. When the drug will be administered for a short time only
D. Are converted by the liver to more active and fat-soluble forms
C. When there is a high correlation between the dose and saturation of receptor sites
ANS: C PTS: 1 D. To determine if a drug is in the therapeutic range

3. The route of excretion of a volatile drug will likely be the: ANS: D PTS: 1
A. Kidneys
B. Lungs 9. A laboratory result indicates that the peak level for a drug is above the minimum toxic
C. Bile and feces concentration. This means that the:
A. Concentration will produce therapeutic effects.
D. Skin
B. Concentration will produce an adverse response.
ANS: B PTS: 1 C. Time between doses must be shortened.
D. Duration of action of the drug is too long.
4. A major disadvantage to IV administration is that:
A. First-pass metabolism is eliminated. ANS: B PTS: 1
B. Needles and sterility are required.
C. Absorption of the drug cannot be slowed after administration. 10. Drugs that are receptor agonists may demonstrate what property?
A. Irreversible binding to the drug receptor site
D. It is significantly more expensive than other routes.
B. Up-regulation with chronic use
ANS: C PTS: 1 C. Desensitization or down-regulation with continuous use
D. Inverse relationship between drug concentration and drug action
5. The nurse practitioner (NP) chooses to give cephalexin every 8 hours based on knowledge of
the drug’s: ANS: C PTS: 1
A. Propensity to go to the target receptor
B. Biological half-life 11. Drugs that are receptor antagonists, such as beta blockers, may cause:
A. Down-regulation of the drug receptor
C. Pharmacodynamics
B. An exaggerated response if abruptly discontinued
D. Safety and side effects
C. Partial blockade of the effects of agonist drugs
ANS: B PTS: 1 D. An exaggerated response to competitive drug agonists

6. Deferasirox is a chelating agent used to treat iron overload by binding iron to render it ANS: B PTS: 1
biologically inactive. This is best characterized as a(n):

, Woo 3 Woo 4
Pharmacotherapeutics for APN Prescribers, 6e Ch02 Pharmacotherapeutics for APN Prescribers, 6e Ch02

12. Factors that affect gastric drug absorption include: B. Change the drugs so they can cross plasma membranes
A. Liver enzyme activity C. Change drug molecules to a form that an excretory organ can excrete
B. Protein-binding properties of the drug molecule D. Make these drugs more ionized and polar to facilitate excretion
C. Lipid solubility of the drug
D. Ability to chew and swallow ANS: C PTS: 1

ANS: C PTS: 1 18. Once they have been metabolized by the liver, the metabolites may be:
A. More active than the parent drug
13. Drugs administered via IV: B. Less active than the parent drug
A. Need to be lipid soluble in order to be easily absorbed C. Totally “deactivated” so they are excreted without any effect
B. Begin distribution into the body immediately D. All of the above
C. Are easily absorbed if they are nonionized
D. May use pinocytosis to be absorbed ANS: D PTS: 1

ANS: B PTS: 1 19. All drugs continue to act in the body until they are changed or excreted. The ability of the
body to excrete drugs via the renal system would be increased by:
14. When a medication is added to a regimen for a synergistic effect, the combined effect of the A. Reduced circulation and perfusion of the kidney
drugs is: B. Chronic renal disease
A. The sum of the effects of each drug individually C. Competition for a transport site from another drug
B. Greater than the sum of the effects of each drug individually D. Increased renal blood flow
C. Less than the effect of each drug individually
D. Not predictable, as it varies with each individual ANS: D PTS: 1

ANS: B PTS: 1 20. Steady state is:
A. The point on the drug concentration curve when absorption exceeds excretion
15. Which of the following statements about bioavailability is true? B. When the peak and trough remain constant
A. Bioavailability issues are especially important for drugs with narrow therapeutic C. When the amount of drug in the body stays below the minimum toxic
ranges or sustained-release mechanisms. concentration
B. All brands of a drug have the same bioavailability. D. All of the above
C. Drugs that are administered more than once a day have greater bioavailability than
ANS: B PTS: 1
drugs given once daily.
D. Combining an active drug with an inert substance does not affect bioavailability.
21. A patient is being treated for pain with hydrocodone. If the patient is then prescribed a
ANS: A PTS: 1 CYP2D6 inhibitor, the likely clinical result is:
A. Hydrocodone toxicity
16. Which of the following statements about the major distribution barriers (blood–brain or fetal– B. Prolonged action of hydrocodone
placental) is true? C. Parasympathetic adverse effects
A. Water soluble and ionized drugs cross these barriers rapidly. D. Inadequate pain control
B. The blood–brain barrier slows the passage of many drugs into and out of brain
ANS: D PTS: 1
cells.
C. The fetal–placental barrier protects the fetus from drugs taken by the mother.
22. Actions taken to reduce drug–drug interaction problems include all of the following EXCEPT:
D. Lipid-soluble drugs do not pass these barriers and are safe for pregnant women. A. Reducing the dosage of one of the drugs
ANS: B PTS: 1 B. Scheduling their administration at different times
C. Prescribing a third drug to counteract the adverse reaction of the combination
17. Drugs are metabolized mainly by the liver via phase I or phase II reactions. The purpose of D. Reducing the dosage of both drugs
both of these types of reactions is to:
A. Inactivate prodrugs before they can be activated by target tissues ANS: C PTS: 1

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller DrREED. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $25.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

64419 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling

Seller

Package deal ·

Exam (elaborations)

TEST BANK Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition Teri Moser Woo and Wendy L. Wright Updated Version

Document information

Subjects

Connected book

More summaries for

Written for